Evotec Biologics advances orthopoxvirus antibodies into Phase 1
Evotec Biologics advanced U.S. Department of War antibodies against orthopoxvirus into Phase 1 clinical studies.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.